Clinical Trials Logo

Clinical Trial Summary

Aging populations experience a decline in adaptive immune system function also known as immunosenesence. Nutritional approaches to stimulate and strengthen the immune system are needed for this growing segment of the population. A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response. Our objective was to examine the immune stimulating effects of dairy protein subjected to ultraviolet radiation (UV-C) radiation treatment process instead of pasteurization. Participants were 21 healthy individuals over 60 years of age who consumed 6 g of the dairy protein or a comparison, soy isoflavone protein, twice a day for eight weeks. DTaP vaccine administered at week 4. Non-parametric t-tests revealed a significant increase in Tetanus antibodies in the dairy group compared to the soy group at week 8. These findings suggest additional benefits of UV-C treated unheated dairy protein as a solution to counteract immunosenescence, but warrant further study in elderly and other populations that might benefit from immune system stimulation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03557463
Study type Interventional
Source University of California, Davis
Contact
Status Completed
Phase N/A
Start date August 1, 2016
Completion date August 30, 2017

See also
  Status Clinical Trial Phase
Completed NCT02651376 - Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients Phase 1/Phase 2
Completed NCT02345135 - Susceptibility to Infections in Ataxia Telangiectasia N/A
Completed NCT04553705 - Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19) Phase 2/Phase 3
Completed NCT00758992 - Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages N/A
Recruiting NCT05907746 - Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency Phase 2
Active, not recruiting NCT02291965 - Blood Samples to Identify Biomarkers of Busulfan
Recruiting NCT04408950 - Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
Completed NCT00923364 - Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC Phase 2
Withdrawn NCT05672654 - Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients N/A
Recruiting NCT05405491 - Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation N/A
Recruiting NCT01800643 - Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Phase 2/Phase 3
Recruiting NCT00001467 - Genetic Analysis of Immune Disorders
Not yet recruiting NCT04447937 - Immunodeficiency in MS
Completed NCT00925925 - Epigenetic Markers of B-Cell Function in Low Birth Weight Infants N/A
Recruiting NCT01861106 - Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations Phase 2
Recruiting NCT06248957 - SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION
Recruiting NCT05027945 - A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome Phase 2
Recruiting NCT05655546 - ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals N/A
Completed NCT03374566 - Immunodeficiency for Severe Epstein-Barr Virus Infection
Terminated NCT01027702 - Donor Lymphocyte Infusion After Alternative Donor Transplantation Phase 1/Phase 2